



ECHO I/DD

Use of Antipsychotics in Intellectual Disability

Joshua Ryan Smith, MD

Echo Autism: Adult Healthcare Disclosures

- Target audience: professionals providing care for adults with IDD
- Objective: To improve the knowledge of primary care providers who care for adults with IDD.
- Speaker Disclosure: **Joshua Smith** has no relationship with any commercial firm having products related to topics discussed at this program. Actual disclosure forms are available upon request.

Objectives

- Appreciate the high prevalence of antipsychotic use for intellectually disabled populations
- Discuss how psychiatric conditions may present in intellectual disabled populations
- Understand the different categories of antipsychotics
- Appreciate the benefits and possible side effects of each antipsychotic category

Antipsychotic for intellectual and developmental disability

- Internationally, use rates range from 21% to 45%
- Only two are FDA-approved for irritability in autism
 - These studies included individuals with co-morbid intellectual disability
 - Risperidone and Aripiprazole
- Long-term use can be associated with the following
 - Hypertension, diabetes, extrapyramidal side effects, tardive dyskinesia

Antipsychotic for intellectual and developmental disability

- However, they can be very helpful in treating the following:
 - Psychosis (from any cause)
 - Mood disorder (bipolar disorder, depression)
 - Aggression due to an underlying psychiatric condition
- Psychiatric co-morbidity is common
- There is limited efficacy in the use of antipsychotics to address behavior that is not related to a co-morbid psychiatric condition

Try to identify what you are treating / **Know the normal**

- **A change in baseline is key, even if occurring over months to years**
- Not every hallucination is psychosis
 - The key to identifying psychosis is a lack of reality testing
 - Hard to do in this population
 - Sensory sensitivity may appear psychotic
 - Traumatic experiences may appear psychotic
- Aggression, oppositional behaviors, or irritability can be psychosis / but not always
 - Externalizing behaviors such as aggression may be due to communication challenges or a reduced ability to communicate

Try to identify what you are treating / **Know the normal**

- A change in baseline is key, even if occurring over months to years
- Depression / Anxiety / Mood disorder / Other psychiatric conditions
 - Evaluate for change in "rhythms"
 - Sleeping, eating, level of activity, ADLs, social engagement
 - Monitor for regressions in other areas
 - Irritability / aggression may also be a symptom

Antipsychotics

Typical or "First Generation"

Atypical or "Second Generation"

Greater EPS risk
Less metabolic risk



Haldol / Haloperidol

Risperdal / Risperidone
Latuda / Lurasidone
Geodon / Ziprasidone

Thorazine / Chlorpromazine

Zyprexa / Olanzapine
Seroquel / Quetapine
Clozaril / Clozapine

Greater metabolic risk
Less EPS risk



Antipsychotics, quick tips

- Atypical antipsychotics have a lower risk of EPS/dystonia/tardive dyskinesia
- Watch the antipsychotic suffix
 - done = high potency atypical antipsychotic (Risperidone)
 - pine = low potency atypical antipsychotic (Quetiapine)
 - azole = partial D2 agonist (Aripiprazole)
 - Effective antidepressant
 - Acts like agonist when dopamine activity is reduced
 - Acts like an agonist when dopamine activity is enhanced

Use them when you need them, but closely monitor

- Broadly, antipsychotics are considered safe in children and adults
- Always monitor for metabolic side effects and conduct an AIMS examination
 - Metabolic monitoring
 - After initiation -> 12 weeks -> 6 months -> annually
 - Waist circumference, triglyceride, blood pressure, HbA1c, fasting glucose

VANDERBILT  UNIVERSITY
MEDICAL CENTER



Thank you!